Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

14 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHSHE2PCCm MnqwTWM2OD13LkewOUAh|ryPIB?= M1n0PFE5PTV7NkGz
KP6.3 M{nudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rvUFQh\A>? MX;JR|UxRTFyLkSyPEDPxE1i M1u5PVE5PTV7NkGz
KP7.7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO1Xno1KGR? Ml3tTWM2OD13NzDuUUA> NWLhUo5uOTh3NUm2NVM>
KB2P3.4 NX7YfpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[y[4k1KGR? NX:yPIx5UUN3ME2xNlQhVSB? NUPoU3BxOTh3NUm2NVM>
KB2P1.21 NUHYOoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGixOo41KGR? MYXJR|UxRTh7MEegcm0h MnnINVg2PTl4MUO=
U373-MG MUHDfZRwfG:6aXOgRZN{[Xl? Mk[0NUDPxE1i M33VXFI1KGh? MmPzTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M{fXZ|E5QTV2N{Gy
T98G MkHuR5l1d3SxeHnjJGF{e2G7 MVGxJO69VSB? M3f0eVI1KGh? MXzJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 MWCxPFk2PDdzMh?=
U87-MG MlLvR5l1d3SxeHnjJGF{e2G7 Ml\4NUDPxE1i NUn0T2ZXOjRiaB?= MkLXTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NW\UeFFNOTh7NUS3NVI>
UVW MV3DfZRwfG:6aXOgRZN{[Xl? M2ThWVUxOCCwTR?= M4fHTFI1KGh? M3z3OGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NXe4W48xOTh7NUS3NVI>
HeLa MXnGeY5kfGmxbjDBd5NigQ>? M4nSblUxOCCwTR?= M1LrSlQhcA>? NUfLVlJ3S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| MXKxPFk2PDdzMh?=
HeLa M{j2UGZ2dmO2aX;uJGF{e2G7 M4nGeVEh|ryPIB?= NIHTcIczPCCq MXzFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MlnSNVg6PTR5MUK=
T98G NV62T2t7TnWwY4Tpc44hSXO|YYm= MUKxJO69VSB? MXyyOEBp M1H2eWVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 MYKxPFk2PDdzMh?=
L3 M2Lw[WN6fG:2b4jpZ{BCe3OjeR?= NYPWN|k1PSEQvF2g MVG5OkBp M2TOdGROW09? NVm3U2J3W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NXH4ZmRNOjBzMkS0OVk>
Granta-519 NWfyXHgxS3m2b4TvfIlkKEG|c3H5 MlPNOUDPxE1i MXm5OkBp MnLMSG1UVw>? MVLTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M2r5WFIxOTJ2NEW5
BT M3vuWWN6fG:2b4jpZ{BCe3OjeR?= NFzxWmg2KM7:TTC= NWnLfldFQTZiaB?= M4Lx[mROW09? NFi5VFRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NESyXXUzODF{NES1PS=>
UPN2 M1PNdmN6fG:2b4jpZ{BCe3OjeR?= NVvsdYhyPSEQvF2g NHnvfW46PiCq M{fodmROW09? MnrWV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MYqyNFEzPDR3OR?=
HBL-2 MWHDfZRwfG:6aXOgRZN{[Xl? NVuybVlkPSEQvF2g Ml3JPVYhcA>? MYrEUXNQ MoOxV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NWjSUodpOjBzMkS0OVk>
JVM-2 NIXtOWNEgXSxdH;4bYMhSXO|YYm= M{L3OFUh|ryPIB?= MWi5OkBp MV;EUXNQ MXHTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NYnhU5U3OjBzMkS0OVk>
Z138 MWHDfZRwfG:6aXOgRZN{[Xl? NIfRbW82KM7:TTC= NHm3Vm46PiCq NHSzZo9FVVOR MYfTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MXqyNFEzPDR3OR?=
RWPE MYrJcpZie2m4ZTDBd5NigQ>? M3:yOVI2KM7:TR?= NY\pfIx1PDhiaB?= NVLTfnF2TE2VTx?= MnXBV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NFXzU2czOTV5NUi2OS=>
VCaP MXTJcpZie2m4ZTDBd5NigQ>? MU[yOUDPxE1? MmjqOFghcA>? MUjEUXNQ MoTNV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> Mnq2NlE2PzV6NkW=
Mouse H2AX−/− ES Cells MofkR5l1d3SxeHnjJGF{e2G7 M3nzZ|IvPSEQvF2= MlvrNlAhcA>? M1rBVnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M1\iPVI{OzV3NEi5
Mouse ATM−/− ES Cells MlPHR5l1d3SxeHnjJGF{e2G7 NXjRXmtKOi53IN88US=> MVuyNEBp NHP4fpdUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> MX6yN|M2PTR6OR?=
H1650 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSyNEDPxE1? MlzpNVQ1KGh? NHrycFVKSzVyPUG1MlQ4KM7:TR?= MkDTNlMzOzl6MEm=
H1650PTEN+ NU[4SmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DjV|IxKM7:TR?= NGrHO5MyPDRiaB?= NW\mdYNOUUN3ME21NE45OyEQvF2= Mn\WNlMzOzl6MEm=
PC-9 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXfotMOjBizszN MX:xOFQhcA>? MYLJR|UxRTVwOEig{txO NVnrPHh{OjN{M{m4NFk>
PC-9PTEN− NF;RVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3rWXIzOCEQvF2= MUSxOFQhcA>? Mn[5TWM2OD14LkWyJO69VQ>? MkLSNlMzOzl6MEm=
MDA-MB-231 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\CXVUh\GG7 MnzvTWM2OD14Lkmg{txO MnnqNlM4PjB2OU[=
MDA-MB-468 NFHlfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi1JIRigQ>? MoXNTWM2OD13LkCg{txO NVTFV2ZpOjN5NkC0PVY>
BT20 M1;lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflS2RXPSCmYYm= NU\VNoYxUUN3ME23Mlch|ryP NV\ZXmh5OjN5NkC0PVY>
HCC1143 M2XrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\4d4I2KGSjeR?= NUK4[GxGUUN3ME2xNU4yKM7:TR?= Mn;RNlM4PjB2OU[=
HCC1937 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrE[o0xPSCmYYm= M4nobWlEPTB;MUKuOkDPxE1? NV7TeoVROjN5NkC0PVY>
Hs578t M4\UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq1JIRigQ>? MUjJR|UxRTVwNjFOwG0> MWCyN|c3ODR7Nh?=
Hs578t(si) NHztcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zF[lUh\GG7 M{LpdWlEPTB;Nz61JO69VQ>? MXSyN|c3ODR7Nh?=
BT474 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5TFI2KGSjeR?= MV3JR|UxRTF7Lkig{txO MmqxNlM4PjB2OU[=
JIMT1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4V5V1PSCmYYm= M3:zVWlEPTB;Nz63JO69VQ>? NXWzSlJxOjN5NkC0PVY>
SKBR3 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW1JIRigQ>? MXzJR|UxRTFzLkGg{txO MkewNlM4PjB2OU[=
SUM159 NGS5PVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rLTFUh\GG7 NYTPPJZwUUN3ME20MlIh|ryP MoL1NlM4PjB2OU[=
CAMA1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3SOUBl[Xl? M4XzVGlEPTB;MUWuPEDPxE1? NVTtSIxDOjN5NkC0PVY>
MCF7 M4DkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLmN4VYPSCmYYm= NHe0O5pKSzVyPUWuPEDPxE1? MUeyN|c3ODR7Nh?=
T47D NV33b4N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7E[XRFPSCmYYm= NF64fppKSzVyPUmuOkDPxE1? M2XXV|I{PzZyNEm2
HCT116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:0NVAxKM7:TR?= MYK0PEBp NHKxSIVFVVOR Mn;FTWM2OD1{LkWg{txOKA>? MUiyOFU4Pzl2MR?=
SW1116 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXKfG9LOTByIN88US=> MYi0PEBp NGfCXZpFVVOR MY\JR|UxRTFyMDFOwG0> NHz1T3EzPDV5N{m0NS=>
HT29 NXLXXY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNFAh|ryP NFXyNXM1QCCq NV3rTWNRTE2VTx?= M{GwZmlEPTB;MUSuO{DPxE1? M4XEcVI1PTd5OUSx
LoVo NHfRelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxNFAh|ryP M1rTXVQ5KGh? NVfCV3NxTE2VTx?= NWTPTW5{UUN3ME2xN{41KM7:TR?= M2q4b|I1PTd5OUSx
HCT-15 M1q3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxNFAh|ryP M2DLe|Q5KGh? MoDqSG1UVw>? NUPKeYxxUUN3ME2xNEDPxE1? Mnu0NlQ2Pzd7NEG=
SW48 NWHQXW1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzSFExOCEQvF2= NInTc401QCCq NEPqbHVFVVOR M1HsVmlEPTB;OT61JO69VQ>? M1\PcVI1PTd5OUSx
C-1 NH3r[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNFAh|ryP MUC0PEBp MknHSG1UVw>? MYHJR|UxRTdwNjFOwG0> NHPyWVgzPDV5N{m0NS=>
RKO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGryVlcyODBizszN NFPtVHU1QCCq NF7wcXFFVVOR NY\aUpRwUUN3ME21Mlkh|ryP NWXLWVRkOjR3N{e5OFE>
HCT116 M{m2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflXmxmOTByIN88US=> M1qxOVQ5KGh? M1fIO2ROW09? NGLCe|RRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MmS3NlQ2Pzd7NEG=
SW1116 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0NVAxKM7:TR?= NXexVmo5PDhiaB?= M4XZb2ROW09? MX7Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh Ml\JNlQ2Pzd7NEG=
HT29 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNfJQyODBizszN MmnEOFghcA>? NYjFVHh4TE2VTx?= NFS1R2xRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NGHjSYczPDV5N{m0NS=>
LoVo NHnvdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4TmEyODBizszN NIPMT|Q1QCCq M3qzZmROW09? NYTRW3BiWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NV7zZVFoOjR3N{e5OFE>
SW48 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW1NVAxKM7:TR?= NY\R[m43PDhiaB?= NVzaUpdHTE2VTx?= NH7Qd5BRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli M1TrU|I1PTd5OUSx
C-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorRNVAxKM7:TR?= MoDQOFghcA>? MX3EUXNQ MonBVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M3qyfFI1PTd5OUSx
RKO NUTLb4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrUWJQyODBizszN Mn\HOFghcA>? MnjPSG1UVw>? M1rU[3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MW[yOFU4Pzl2MR?=
HCT116 NFfCXIFHfW6ldHnvckBCe3OjeR?= NXLMZYwzOTBibl2= NXfjNoJsOTJiaB?= NWDJV3BoTE2VTx?= M3[1Umlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= MVyyOFU4Pzl2MR?=
HT29 MYTGeY5kfGmxbjDBd5NigQ>? MY[xNEBvVQ>? NWrPO3NLOTJiaB?= MlTYSG1UVw>? MV3JcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? NWTKXIs5OjR3N{e5OFE>
TE-6 NILmV|ZHfW6ldHnvckBCe3OjeR?= MVy1JO69VSB? Mkm5NVIhcA>? Mne0SG1UVw>? NIXCTIZKdmS3Y3XzJGczN01iYYLy[ZN1 NHPud2IzPDJzOUG2OC=>
TE-6 NVTmcpl[TnWwY4Tpc44hSXO|YYm= NUDIeYJYPSEQvF2g MkXVNlQhcA>? Mn6ySG1UVw>? MWfJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq NHfvXWwzPDJzOUG2OC=>
Hep3B MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj4WJI1OCEQvF2g NGG1VHo4OiCq MVfEUXNQ Ml7qV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> NX2yZ|ZJOjVyN{K3OVI>
Huh7 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL2OFAh|ryPIB?= M2ez[lczKGh? MnrJSG1UVw>? M3;nVHN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS Ml3qNlUxPzJ5NUK=
Hep3B Mn;KSpVv[3Srb36gRZN{[Xl? MWS0NEDPxE1i MnvwNlQhcA>? MYPEUXNQ M1zhbWlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= NEXWXVUzPTB5Mke1Ni=>
Huh7 M1rWemZ2dmO2aX;uJGF{e2G7 M{TLVVQxKM7:TTC= M2T6elI1KGh? NEHieppFVVOR M3zD[mlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= M1frcVI2ODd{N{Wy
Hep3B NULINmE5TnWwY4Tpc44hSXO|YYm= NXrLdJZRPDBizszNJC=> MVqyOEBp NFz3coRFVVOR M2rHSmlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= M2XrTVI2ODd{N{Wy
Huh7 M1TpNmZ2dmO2aX;uJGF{e2G7 MkLLOFAh|ryPIB?= NWn1OW5{OjRiaB?= NUjMcItWTE2VTx?= MUjJcoR2[2W|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF? NYnJNWNKOjVyN{K3OVI>
SGC-7901 M4\SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LYSFMxyqEQvF2= M1S2TVQ5KGh? NFvre2hFVVOR NVjyXW5ESmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MYSyOVc3PzB5Nh?=
COLO-800 M3jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PNZWlEPTB;MD60OFE3PCEQvF2= MVnTRW5ITVJ?
EoL-1- M1rxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2PZhKSzVyPUCuOVY1PDZizszN NFfLUIhUSU6JRWK=
NCI-H209 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwOUG1OVYh|ryP NHTEU4VUSU6JRWK=
ES1 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMUG0NFgh|ryP NVHSNI1PW0GQR1XS
NKM-1 M{\BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nJ[WlEPTB;MT6yOVM1PyEQvF2= NXTBUXFGW0GQR1XS
NTERA-S-cl-D1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLWdJZKSzVyPUGuN|M{PDFizszN M1m4NHNCVkeHUh?=
MHH-ES-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwNkKwOlch|ryP NHXrSWdUSU6JRWK=
ES8 M3vmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P1RmlEPTB;MT63NlQyPCEQvF2= NUKxXIRUW0GQR1XS
NCI-H720 NFPPb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwMkC2PVkh|ryP NX71T2t4W0GQR1XS
EW-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjjRVQyUUN3ME2yMlI4PTN2IN88US=> M{W1NXNCVkeHUh?=
D-566MG MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjXT4NKSzVyPUKuOFQ2PjhizszN NIrOfo1USU6JRWK=
697 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorOTWM2OD1{Lki0NVc{KM7:TR?= NWO3UHpbW0GQR1XS
ES5 NYH2c4VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T5c2lEPTB;Mj64PFE5QSEQvF2= NVPDWWhyW0GQR1XS
COLO-684 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHRUItKSzVyPUOuOVE3QTZizszN NVTpUmY3W0GQR1XS
ML-2 M2[4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2WWlEPTB;Mz62NFA2QCEQvF2= NEPRVJFUSU6JRWK=
MC-IXC M3HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDyTWM2OD1|Lk[zN|k{KM7:TR?= Mnf0V2FPT0WU
DB MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL3TVJNUUN3ME2zMlY2PDR6IN88US=> MUfTRW5ITVJ?
HCC2218 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\2UWNDUUN3ME2zMlc{OTB|IN88US=> MlOxV2FPT0WU
NCI-H510A M3\yRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPKT3hrUUN3ME2zMlgzPzJ2IN88US=> M2rzRXNCVkeHUh?=
NCI-H526 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNwOE[5OVgh|ryP NXvremNzW0GQR1XS
MV-4-11 M{XtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrOWlEPTB;ND6xN|M{PCEQvF2= NX;1TGRPW0GQR1XS
PA-1 NV3jdW41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvBXG13UUN3ME20MlI2OjlizszN NIXld|FUSU6JRWK=
EW-22 NXPVWJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nkUmlEPTB;ND6zOVg3KM7:TR?= NWTJVWlqW0GQR1XS
KASUMI-1 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD12LkSwNVA6KM7:TR?= NF3NVVRUSU6JRWK=
LU-139 M3;abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsTWM2OD12Lke1PFI6KM7:TR?= M1vXe3NCVkeHUh?=
SBC-1 M4ftZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3jboxKSzVyPUSuPFA6ODhizszN M2XLfHNCVkeHUh?=
H4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTVTWM2OD12Lki5OFQ{KM7:TR?= MYrTRW5ITVJ?
EW-11 NYfPTVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CUFRXUUN3ME21MlA5ODd{IN88US=> NUXCOVh3W0GQR1XS
NBsusSR MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm1TWM2OD13LkGyNFU2KM7:TR?= M3HHNHNCVkeHUh?=
RPMI-8226 NWrUW4tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjtclF7UUN3ME21MlE2OjR2IN88US=> NHX0RWhUSU6JRWK=
DEL MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fIVmlEPTB;NT6yNFAxPiEQvF2= MVLTRW5ITVJ?
ES4 NVLGfnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYeybZlVUUN3ME21MlUyOzh7IN88US=> MlvBV2FPT0WU
GCT M2XLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkO5FKSzVyPUWuOVY5PTZizszN MlGxV2FPT0WU
NCI-H1048 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z5PWlEPTB;NT65O|I4OyEQvF2= M3vWZXNCVkeHUh?=
NCI-SNU-1 NVTkTpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZwMEKyJO69VQ>? NIPuclBUSU6JRWK=
ES7 NGnofnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xTWM2OD14LkCzOVc4KM7:TR?= MkLqV2FPT0WU
SW982 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;0UmlEPTB;Nj6wPVE{PyEQvF2= MmGzV2FPT0WU
L-363 NHv4boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrvVHFKSzVyPU[uN|M6PzRizszN NWXJNYpwW0GQR1XS
HT-1080 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzBTWM2OD14LkS5Olg{KM7:TR?= MmS4V2FPT0WU
HAL-01 M4DabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH1dZpKSzVyPU[uOVExQSEQvF2= M4rZe3NCVkeHUh?=
NB14 M3HBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHtUYhlUUN3ME22MlY1ODN7IN88US=> MYHTRW5ITVJ?
EW-13 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ufWRKSzVyPU[uO|c1OjRizszN M1ThN3NCVkeHUh?=
NY NWTzW|JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTZwOUS2NFUh|ryP NH3xdYRUSU6JRWK=
NCI-SNU-5 NY\JTZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL3boNKSzVyPUeuNVA1OzNizszN MkTqV2FPT0WU
MS-1 NV7EPHlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\LbGlEPTB;Nz6xO|Q6PCEQvF2= NXfU[HV1W0GQR1XS
EW-16 NYjzcXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdwM{G4OlEh|ryP NWPH[G5qW0GQR1XS
LU-65 NWPBdYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDUPYhKSzVyPUeuOFg1OTdizszN MUPTRW5ITVJ?
HGC-27 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrVTWM2OD15LkeyNVc{KM7:TR?= MlvpV2FPT0WU
CTB-1 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPZZlZKSzVyPUeuO|YyPzVizszN NYXLPYFuW0GQR1XS
5637 NYnnRng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmexTWM2OD15LkmyPFYh|ryP NV\V[2tPW0GQR1XS
U251 NH\QdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTdwOUSwNVYh|ryP NGTSfmxUSU6JRWK=
HOS NYC1SJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRThwMkOwNFch|ryP NHrISVhUSU6JRWK=
DOHH-2 NEHYdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HU[mlEPTB;OD6yN|U5KM7:TR?= MoX2V2FPT0WU
EW-1 NWjOe21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDBTWM2OD16LkOwNFg5KM7:TR?= M1jodHNCVkeHUh?=
BV-173 NFHoeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRThwNUW1OEDPxE1? NFTveXhUSU6JRWK=
8-MG-BA MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwNki5PFgh|ryP MnTuV2FPT0WU
NB69 NYjse3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6wNHJKSzVyPUiuO|A6OjFizszN Mn\tV2FPT0WU
NCI-H69 NWTPdo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv3TWM2OD17LkmwPVYyKM7:TR?= MWjTRW5ITVJ?
RS4-11 NIPyNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LicGlEPTB;MUGuNlIxQCEQvF2= MkezV2FPT0WU
ONS-76 M2\D[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFzLkK5OFch|ryP NHvZTnZUSU6JRWK=
SF539 NX\KeoZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnIbVdKSzVyPUGxMlQ5QDlizszN NWT4TJZbW0GQR1XS
HuO-3N1 NUe1fWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[wfoZKSzVyPUGxMlU4QTZizszN Mlu1V2FPT0WU
NCI-H1651 M3\z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rwdmlEPTB;MUKuN|EyPSEQvF2= NWjac3F5W0GQR1XS
KARPAS-45 NFfuNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\vTWM2OD1zMj6zO|Yh|ryP NVXGOWtjW0GQR1XS
SK-NEP-1 M{fUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF{LkS2NFkh|ryP MYLTRW5ITVJ?
LAMA-84 NInYeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO3e|BKSzVyPUGzMlExQTVizszN NWDoTGg5W0GQR1XS
NCI-H1155 NE\meZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX4TWM2OD1zMz6yPFU3KM7:TR?= M4TmOXNCVkeHUh?=
CTV-1 NGHaS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF|LkS0OUDPxE1? M4nhU3NCVkeHUh?=
QIMR-WIL NVLRbpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;1TWM2OD1zMz63PFE1KM7:TR?= Mo\WV2FPT0WU
H9 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL0XIROUUN3ME2xN{45PDd3IN88US=> NGXDe4JUSU6JRWK=
SK-MEL-1 NVHlNHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDYVWlUUUN3ME2xN{46OzR5IN88US=> MUPTRW5ITVJ?
HD-MY-Z MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTMTWM2OD1zND6wOlM4KM7:TR?= MYHTRW5ITVJ?
TI-73 M2X0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfNeJgyUUN3ME2xOE4zOzV4IN88US=> MX\TRW5ITVJ?
JVM-3 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHXcXY4UUN3ME2xOU42PzF4IN88US=> NWGzO2M6W0GQR1XS
D-247MG MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j3TGlEPTB;MUWuOVk{KM7:TR?= MYrTRW5ITVJ?
VA-ES-BJ NWf5dYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonnTWM2OD1zNT62NFk4KM7:TR?= NYPDUW1jW0GQR1XS
NOS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;X[mFKSzVyPUG1MlY2OjJizszN NWTGO4NuW0GQR1XS
MOLT-4 NYG3fGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPTe3lKSzVyPUG2Mlc2OiEQvF2= NHTkbW9USU6JRWK=
Mo-T MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVniTWx5UUN3ME2xO{4xQDR7IN88US=> MkX5V2FPT0WU
NCI-H1770 NEjaW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF5LkG1OFMh|ryP NFyyVFBUSU6JRWK=
COLO-320-HSR MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nLOGlEPTB;MUeuNVgzPyEQvF2= MnHMV2FPT0WU
TE-12 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjveWJKSzVyPUG3MlcxPTRizszN NGW2XHlUSU6JRWK=
NCI-H82 M4P0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrsT3lKSzVyPUG3Mlg4OjhizszN NWnmOWxrW0GQR1XS
NEC8 M4OyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCbmlEPTB;MUiuNVMyPiEQvF2= NVLBW4pFW0GQR1XS
HSC-3 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULlU3V{UUN3ME2xPE44PDF2IN88US=> NV7KdVV7W0GQR1XS
NCI-H1092 M2jQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXpZlNKSzVyPUG4Mlc2QTVizszN MX3TRW5ITVJ?
NCI-H292 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF7LkC0PFkh|ryP MVfTRW5ITVJ?
L-428 NHLCXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHGV4o{UUN3ME2xPU42PTlizszN NHHzd5pUSU6JRWK=
LU-134-A MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yxfWlEPTB;MUmuOVczKM7:TR?= Mk\5V2FPT0WU
GI-ME-N MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LQbWlEPTB;MUmuOVc1PyEQvF2= M{S2Z3NCVkeHUh?=
ALL-PO NW[2N|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHrTnFKSzVyPUG5MlU6PzJizszN NFvtXVlUSU6JRWK=
D-283MED NGfiPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF7LkmxOUDPxE1? NIj2SFhUSU6JRWK=
D-423MG NUnSUpJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF7Lkm5Olch|ryP MkLiV2FPT0WU
CAKI-1 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESwbVZKSzVyPUKwMlIzOTlizszN M1TRTnNCVkeHUh?=
ETK-1 NFHFNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJyLkK2NVUh|ryP MXnTRW5ITVJ?
G-402 NUHLXIQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:5c4JKSzVyPUKwMlU{OzRizszN M4rzdnNCVkeHUh?=
HL-60 NVT1doE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJzLkG2NVMh|ryP Mk\tV2FPT0WU
A2058 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDGU2NKSzVyPUKxMlQ1PzdizszN MWPTRW5ITVJ?
CHP-212 M1vUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJzLkmwOVEh|ryP NVXONm9IW0GQR1XS
KY821 NVLMe2VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJzLkm3OUDPxE1? NVyxO5k4W0GQR1XS
TYK-nu NFfXRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrOTWM2OD1{Mj6wOlUyKM7:TR?= NWrneoR[W0GQR1XS
JVM-2 NEDRPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3VO4s3UUN3ME2yNk4zQTh|IN88US=> NELheGlUSU6JRWK=
KU812 M13DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;3VlN{UUN3ME2yNk44OzF{IN88US=> M3yxVnNCVkeHUh?=
MKN28 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULVVHZuUUN3ME2yNk46ODF3IN88US=> M3zLVnNCVkeHUh?=
ECC10 NWDrPGJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP5OlZKSzVyPUKzMlc1OSEQvF2= NF7QSHFUSU6JRWK=
BHT-101 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW0TWM2OD1{ND6wNFA5KM7:TR?= NEDLenRUSU6JRWK=
DU-4475 NH;vPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\6PFRsUUN3ME2yOE4{OzN5IN88US=> MVXTRW5ITVJ?
769-P NF\ZcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD1b2dSUUN3ME2yOE45PDZ4IN88US=> NWnnUHRyW0GQR1XS
HEC-1 NYTjUWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ3LkS0OUDPxE1? M1HLO3NCVkeHUh?=
MOLT-13 M2XhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWzTWM2OD1{NT61N|MyKM7:TR?= NFvO[GtUSU6JRWK=
8505C MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\KOYlDUUN3ME2yOk41QTd5IN88US=> MVXTRW5ITVJ?
GB-1 M3vLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPoT4dxUUN3ME2yOk44OTd4IN88US=> NFHaeXZUSU6JRWK=
SF126 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT6W3NKSzVyPUK2Mlc3PDhizszN NXPKUpRkW0GQR1XS
A4-Fuk Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7WTWM2OD1{Nz6xNlcyKM7:TR?= NFHxSpJUSU6JRWK=
OVCAR-8 NXTzW|Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\NWmlEPTB;MkeuNVU{QSEQvF2= NH7FdWdUSU6JRWK=
NCI-H1304 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0OmlEPTB;MkeuOVQh|ryP MmfuV2FPT0WU
GR-ST NXvWZXppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLxT2NEUUN3ME2yPE4xPDdizszN NG[4OpJUSU6JRWK=
G-401 M3P4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy5SmxWUUN3ME2yPE42ODl4IN88US=> NXjidJFoW0GQR1XS
LXF-289 NEXORpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPsSJd5UUN3ME2yPE42PjVzIN88US=> M3jwWnNCVkeHUh?=
DBTRG-05MG NHS0NnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5RWhKSzVyPUK4MlkzODRizszN NGPlcW5USU6JRWK=
YKG-1 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ7Lki2PEDPxE1? NX\hVohHW0GQR1XS
GAMG M1;nVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\xfJVKSzVyPUK5Mlk6OyEQvF2= M2nORXNCVkeHUh?=
HCT-116 M2fMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1fY5KSzVyPUOwMlA2PDhizszN M1TOeXNCVkeHUh?=
S-117 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTNzLkKyOVch|ryP MX3TRW5ITVJ?
NCI-H1693 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jJdGlEPTB;M{OuOlU1OiEQvF2= MmLXV2FPT0WU
A427 M4DjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG5blZKSzVyPUOzMlk6PzZizszN MWDTRW5ITVJ?
HT-29 NGr5RXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnTUnJKSzVyPUO0MlYxOzJizszN M2jrfXNCVkeHUh?=
P12-ICHIKAWA NFHVdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN2Lke0PVEh|ryP M4PY[XNCVkeHUh?=
CAL-51 NVH4WIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN3LkC3NFkh|ryP M{XpVnNCVkeHUh?=
Ramos-2G6-4C10 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMOmlEPTB;M{WuNlQzPSEQvF2= MlX0V2FPT0WU
SCH Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fhd2lEPTB;M{[uOFE4PCEQvF2= M2XtT3NCVkeHUh?=
SK-MEL-24 NHLGV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN4LkmwOFQh|ryP NXXRbJQ3W0GQR1XS
SW1573 M3\5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTaOZRJUUN3ME2zPE44OjF4IN88US=> NVLGcFlsW0GQR1XS
BALL-1 M17Bb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnEOJpKSzVyPUO5MlIyOjlizszN NFfqbmhUSU6JRWK=
BE-13 NIDBV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3PfZB1UUN3ME2zPU4{OjlizszN NFXNT3VUSU6JRWK=
GI-1 M4Doemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\aWmZCUUN3ME2zPU45PjR5IN88US=> MWDTRW5ITVJ?
GOTO MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LoVmlEPTB;M{muPVE{QSEQvF2= MnzMV2FPT0WU
A673 M1GwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD12MT6wN|Q{KM7:TR?= M3\ZNnNCVkeHUh?=
KG-1 M1HjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD12Mz6zPVQh|ryP M4nMZXNCVkeHUh?=
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjWOHJKSzVyPUS0MlA3PjZizszN NULjPZlZW0GQR1XS
MFM-223 M1jwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftcmlEPTB;NESuNVIzQCEQvF2= MVTTRW5ITVJ?
OAW-42 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyzSZY6UUN3ME20OE4zPjR|IN88US=> MYXTRW5ITVJ?
C8166 M4jwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\xTWM2OD12NT6wPFIzKM7:TR?= NXy4enV6W0GQR1XS
LU-99A M37xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXMTWM2OD12Nj6xN|IzKM7:TR?= NXXjVVF6W0GQR1XS
NCI-H23 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHQUmIzUUN3ME20Ok4yPzh3IN88US=> MUHTRW5ITVJ?
HO-1-N-1 M4S1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq3XFNoUUN3ME20O{4xQTl6IN88US=> NWDIdZpoW0GQR1XS
A3-KAW NEXNPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR5LkGwNFch|ryP MULTRW5ITVJ?
CGTH-W-1 NH6wb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHV[lV4UUN3ME20O{42ODZ7IN88US=> MUnTRW5ITVJ?
DJM-1 M3;1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO2U2xKSzVyPUS3MlU1OTNizszN MlzjV2FPT0WU
A101D M{nMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfVWI1DUUN3ME20O{43OzV5IN88US=> MoLXV2FPT0WU
BB30-HNC NIrsNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR6LkOwO|Ih|ryP MoDLV2FPT0WU
T98G NYL1VVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrw[ZNKSzVyPUS4MlQ3OzNizszN M2TGOnNCVkeHUh?=
NCI-H1573 NHrneXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD1TWM2OD12OT60OFYzKM7:TR?= MojSV2FPT0WU
MEG-01 M1P3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnjVW0xUUN3ME20PU44PDFzIN88US=> NEPQZppUSU6JRWK=
WM-115 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y0WmlEPTB;NEmuPVIzOiEQvF2= NFfieHlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID